Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial

被引：0

作者：

Aggarwal, Rohit ^{[1
]}

Charles-Schoeman, Christina ^{[2
]}

Schessl, Joachim ^{[3
]}

Bata-Csorgo, Zsuzsanna ^{[4
]}

Dimachkie, Mazen ^{[5
]}

Griger, Zoltan ^{[6
]}

Moiseev, Sergey ^{[7
]}

Oddis, Chester ^{[1
]}

Schiopu, Elena ^{[8
]}

Vencovsky, Jiri ^{[9
]}

Beckmann, Irene ^{[10
]}

Clodi, Elisabeth ^{[10
]}

Levine, Todd ^{[11
]}

机构：

[1] Univ Pittsburgh, Pittsburgh, PA USA

[2] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA

[3] Med Univ Munich, Friedrich Baur Inst, Munich, Germany

[4] Univ Szeged, Fac Med, Szeged, Hungary

[5] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[6] Univ Debrecen, Debrecen, Hungary

[7] First Moscow State Med Univ, Moscow, Russia

[8] Univ Michigan, Ann Arbor, MI 48109 USA

[9] Inst Rheumatol, Prague, Czech Republic

[10] Octapharma PPG, Vienna, Austria

[11] Phoenix Neurol Associates LTD, Phoenix, AZ USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0695

引用

页码：1409 / 1412

页数：4

共 50 条

[1] Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
Aggarwal, Rohit
Charles-Schoeman, Christina
Schessl, Joachim
Bata-Csorgo, Zsuzsanna
Dimachkie, Mazen
Griger, Zoltan
Moiseev, Sergey
Oddis, Chester
Schiopu, Elena
Vencovsky, Jiri
Irene, Beckmann
Elisabeth, Clodi
Levine, Todd
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[2] THE PRODERM STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG (OCTAGAM 10%) IN PATIENTS WITH ACTIVE DERMATOMYOSITIS
Aggarwal, R.
Charles-Schoeman, C.
Schessl, J.
Bata-Csorgo, Z.
Dimachkie, M. M.
Griger, Z.
Moiseev, S.
Oddis, C. V.
Schiopu, E.
Vencovsky, J.
Beck-Mann, I.
Clodi, E.
Levine, T.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 428 - 429
[3] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETY
Aggarwal, R.
Charles-Schoeman, C.
Schessl, J.
Bata-Csorgo, Z.
Dimachkie, M.
Griger, Z.
Moiseev, S.
Oddis, C. V.
Schiopu, E.
Vencovsky, J.
Beckmann, I.
Levine, T.
Clodi, E.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 4 - 5
[4] Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study")
Aggarwal, Rohit
Charles-Schoeman, Christina
Schessl, Joachim
Dimachkie, Mazen M.
Beckmann, Irene
Levine, Todd
MEDICINE, 2021, 100 (01) : E23677
[5] Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial
Aggarwal, Rohit
Charles-Schoeman, Christina
Schessl, Joachim
Werth, Victoria
Bata-Csorgo, Zsuzsanna
Dimachkie, Mazen
Griger, Zoltan
Moiseev, Sergey
Oddis, Chester
Schiopu, Elena
Vencovsky, Jiri
Beckmann, Irene
Clodi, Elisabeth
Levine, Todd
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4449 - 4450
[6] The ProDERM study: A randomized, double-blinded, placebo controlled trial of IVIG (Octagam 10%) in patients with dermatomyositis
Aggarwal, R.
Charles-Schoeman, C.
Schessl, J.
Bata-Csorgo, Z.
Dimachkie, M.
Griger, Z.
Moiseev, S.
Oddis, C.
Schiopu, E.
Vencovsky, J.
Beckmann, I.
Clodi, E.
Levine, T.
NEUROMUSCULAR DISORDERS, 2020, 30 : S133 - S133
[7] Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Inman, Robert D.
Davis, John C., Jr.
van der Heijde, Desiree
Dickman, Laura
Sieper, Joachim
Kim, Sung Il
Mack, Michael
Han, John
Visvanathan, Sudha
Xu, Zhenhua
Su, Benjamin
Beutler, Anna
Braun, Juergen
ARTHRITIS AND RHEUMATISM, 2008, 58 (11): : 3402 - 3412
[8] Randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis
Coyle, K.
Pokrovnichka, A.
French, K.
Joe, G.
Shrader, J.
Swan, L.
Cabalar, I.
Harris-Love, M.
Plotz, P.
Miller, F.
Gourley, M.
ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S923 - S924
[9] THE SAFETY AND TOLERABILITY OF LACOSAMIDE IN RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II/III CLINICAL TRIALS
Gil-Nagel, A.
Biton, V.
Fountain, N.
Rosenow, F.
Hebert, D.
Doty, P.
EPILEPSIA, 2009, 50 : 110 - 110
[10] Safety and Tolerability of Dexpramipexole for the Treatment of ALS: Results from the Randomized, Double-Blind, Placebo-Controlled Trial, EMPOWER
Van den Berg, Leonard
Cudkowicz, Merit
Shefner, Jeremy
Mitsumoto, Hiroshi
Mora, Jesus
Ludolph, Albert
Hardiman, Orla
Ingersoll, Evan
Archibald, Donald
Li, Xiaoxi
Dong, Yingwen
Kerr, Douglas
Farwell, Wildon
NEUROLOGY, 2013, 80

← 1 2 3 4 5 →